Gepadif

Gepadif – the combined drug with hepatoprotective action.

Form of release and structure

Gepadif release in the following dosage forms:

• Capsules: gelatinous, firm, pale chocolate color the case with a text of "H.S.D" and dark and chocolate color a lid with a text of "hepadif"; contents of capsules – powder of light yellow color with a brown shade (on 10 pieces in blisters, on 3, 5 or 10 blisters in a cardboard pack);
• Powder for preparation of injection solution: heterogeneous, porous weight from brownish-pink till light pink color (in glass bottles, on 5 and 10 bottles in a cardboard pack).

Active agents are a part of 1 capsule:

• Anti-toxic fraction of extract of a liver – 12,5 mg;
• Pyridoxine a hydrochloride – 25 mg;
• Adenine a hydrochloride – 2,5 mg;
• Carnitine оротат – 150 mg;
• Cyanocobalamine – 0,125 mg;
• Riboflavinum – 0,5 mg.

Auxiliary components: lactose, D-sorbitol, colloid silicon dioxide, magnesium stearate.

Active agents are a part of 1 bottle of powder for preparation of solution for injections:

• Anti-toxic fraction of extract of a liver – 25 mg;
• DL carnitine a hydrochloride – 184 mg;
• Carnitine оротат – 300 mg;
• Pyridoxine a hydrochloride – 25 mg;
• Adenosine – 5 mg;
• Cyanocobalamine – 0,25 mg.

Auxiliary components: methylparahydroxybenzoate, D-Mannitolum, пропилпарагидроксибензоат.

Indications to use

• Chronic and acute hepatitises (as a part of complex treatment);
• Cirrhosis (as a part of complex treatment);
• Fatty dystrophy of a liver;
• The medicinal intoxication connected with long reception of antitubercular, antineoplastic and other drugs;
• Alcoholic and toxic damages of a liver;
• Exogenous poisonings;
• Intoxications at chronic somatic diseases;
• Disintoxication therapy in surgical practice (before and after carrying out the general anesthesia).

Contraindications

Gepadif's use is contraindicated at hypersensitivity to drug components.

Route of administration and dosage

It is recommended to begin treatment with parenteral administration of drug then pass to oral administration of Gepadif.

Parenterally the drug is administered intravenously kapelno. The adult daily dose makes 1 bottle. Before introduction contents of a bottle it is necessary to dissolve 5% of solution of glucose (dextrose) in 400-500 ml. In cases of intolerance of glucose cultivation of contents of a bottle in 20 ml of water for injections is possible, at the same time solution is entered intravenously slowly, struyno.

The newborn Gepadif appoint at the rate of 1/5 adult doses (powder should be dissolved in 5 ml 5% of solution of a dextrose, then 1 ml of the received solution it is necessary to dissolve 5% of solution of a dextrose in 30-40 ml). The drug should be administered once a day intravenously kapelno (through a perfusor of "Lineomat"). A therapy course – 7-10 days.

To children of 7-14 years appoint 1 bottle a day. Contents of a bottle dissolve 5% of solution of a dextrose in 300 ml. A therapy course – 15 days then pass to Gepadif's reception in the form of capsules.

Gepadif in the form of tablets accept inside, irrespective of meal.

The scheme of use of drug is defined by age:

• Adults – 2-3 times a day on 2 capsules;
• Children of 7-14 years – 2-3 times a day on 1-2 capsules;
• Children up to 7 years – 2 times a day on 1 capsule.

If necessary contents of the capsule can be parted in 50 ml of water or juice (milk should not be used).

The therapy course usually makes not less than 2 months. Depending on indications carrying out 2-3 repeated courses in a year is possible.

Side effects

During treatment development of such side effects is possible: skin rash, nausea and abdominal pain.

Special instructions

Simultaneous introduction of Gepadif with insulin, vitamins and other drugs in one syringe is not recommended.

It is impossible to dissolve with saline solutions drug.

Medicinal interaction

Data on interaction with other medicines are absent.

Terms and storage conditions

To store in protected from light, the place, dry, unavailable to children, at a temperature up to 25 °C.

Period of validity:

• Powder for preparation of solution for injections – 3 years;
• Capsules – 5 years.